Christa Balanoff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Christa Balanoff has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Kelsey E. Larson
Division of Breast Surgical Oncology, Department of Surgery, University of Kansas Medical Center, Kansas City, USA
20 shared publications - Amanda L. Amin
Case Western Reserve University School of Medicine, Case Western Reserve University, Cleveland, OH, United States; University Hospitals Research in Surgical Outcomes and Effectiveness (UH-RISES), University Hospitals Cleveland Medical Center, Cleveland, OH, United States; Division of Surgical Oncology, Department of Surgery, University Hospitals Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, United States
15 shared publications Jamie Wagner
University of Kansas Cancer Center, Kansas City, USA
14 shared publications- Bruce F. Kimler
University of Kansas Medical Center 8 Department of Radiation Oncology Kansas City, Kansas
12 shared publications - Andrew K. Godwin
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, USA
11 shared publications Anuj Shrestha
11 shared publications
Latest Publications
- 20 January 2025
- Published by Springer Nature in Journal of Community Health
- Vol. 50 (3) , 546-552
Evaluation of the Current Knowledge Base of Breast Cancer Screening Recommendations in the Transgender Population at an Academic Medical Center
Health care disparities within the LGBTQIA+ community are readily apparent. Guidelines have been published regarding breast cancer screening for transgender individuals. Uptake of these recommendations is widely unknown. The purpose of this study is to determine the current knowledge base of providers regarding these recommendations within our academic hospital system. A voluntary, anonymous survey was e-mailed to 303 recipients via RedCap to physicians within our academic hospital system. This assessed the respondents’ current knowledge and comfort regarding breast cancer screening recommendations in the transgender population. 85 responses were received for a response rate of 28.1%. Descriptive statistics for all survey questions was conducted. 82.4% of respondents report caring for transgender patients. 62.4% report that they are not familiar with the current screening recommendations, and few (10.6%) have received formal education regarding the topic. The majority of respondents reported that they would be interested in receiving formal training. The results suggest that there is no difference in how individuals rate their current comfort level discussing breast cancer screening recommendations for the transgender population despite their current level of education. Our findings suggest that, while the majority of providers within our academic hospital system care for transgender patients, they are unfamiliar with current breast cancer screening recommendations and have received no formal training. The results also suggest that providers are interested in receiving formal education.
- 20 January 2025
- Published by Springer Nature in Journal of Community Health
- Vol. 50 (3) , 546-552
Evaluation of the Current Knowledge Base of Breast Cancer Screening Recommendations in the Transgender Population at an Academic Medical Center
Health care disparities within the LGBTQIA+ community are readily apparent. Guidelines have been published regarding breast cancer screening for transgender individuals. Uptake of these recommendations is widely unknown. The purpose of this study is to determine the current knowledge base of providers regarding these recommendations within our academic hospital system. A voluntary, anonymous survey was e-mailed to 303 recipients via RedCap to physicians within our academic hospital system. This assessed the respondents’ current knowledge and comfort regarding breast cancer screening recommendations in the transgender population. 85 responses were received for a response rate of 28.1%. Descriptive statistics for all survey questions was conducted. 82.4% of respondents report caring for transgender patients. 62.4% report that they are not familiar with the current screening recommendations, and few (10.6%) have received formal education regarding the topic. The majority of respondents reported that they would be interested in receiving formal training. The results suggest that there is no difference in how individuals rate their current comfort level discussing breast cancer screening recommendations for the transgender population despite their current level of education. Our findings suggest that, while the majority of providers within our academic hospital system care for transgender patients, they are unfamiliar with current breast cancer screening recommendations and have received no formal training. The results also suggest that providers are interested in receiving formal education.
- Open Access
- 5 October 2023
- Published by Elsevier in The American Journal of Surgery
- Vol. 227, 218-223
Evaluation of learning curve with Indocyanine Green (IcG) versus blue dye for sentinel lymph node biopsy in breast cancer
- 5 October 2023
- Published by Elsevier in The American Journal of Surgery
- Vol. 227, 218-223
Open AccessEvaluation of learning curve with Indocyanine Green (IcG) versus blue dye for sentinel lymph node biopsy in breast cancer
- 11 July 2023
- Published by Elsevier in The American Journal of Surgery
- Vol. 228, 5-9
Advanced degrees, gender, and professional rank in surgery, disparities in academic medicine
- 11 July 2023
- Published by Elsevier in The American Journal of Surgery
- Vol. 228, 5-9
Advanced degrees, gender, and professional rank in surgery, disparities in academic medicine
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)
Purpose:Addition of carboplatin (Cb) to anthracycline chemotherapy improves pathologic complete response (pCR), and carboplatin plus taxane regimens also yield encouraging pCR rates in triple-negative breast cancer (TNBC). Aim of the NeoSTOP multisite randomized phase II trial was to assess efficacy of anthracycline-free and anthracycline-containing neoadjuvant carboplatin regimens.Patients and Methods:Patients aged ≥18 years with stage I–III TNBC were randomized (1:1) to receive either paclitaxel (P) weekly × 12 plus carboplatin AUC6 every 21 days × 4 followed by doxorubicin/cyclophosphamide (AC) every 14 days × 4 (CbP → AC, arm A), or carboplatin AUC6 + docetaxel (D) every 21 days × 6 (CbD, arm B). Stromal tumor-infiltrating lymphocytes (sTIL) were assessed. Primary endpoint was pCR in breast and axilla. Other endpoints included residual cancer burden (RCB), toxicity, cost, and event-free (EFS) and overall survival (OS).Results:One hundred patients were randomized; arm A (n = 48) or arm B (n = 52). pCR was 54% [95% confidence interval (CI), 40%–69%] in arm A and 54% (95% CI, 40%–68%) in arm B. RCB 0+I rate was 67% in both arms. Median sTIL density was numerically higher in those with pCR compared with those with residual disease (20% vs. 5%; P = 0.25). At median follow-up of 38 months, EFS and OS were similar in the two arms. Grade 3/4 adverse events were more common in arm A compared with arm B, with the most notable differences in neutropenia (60% vs. 8%; P < 0.001) and febrile neutropenia (19% vs. 0%; P < 0.001). There was one treatment-related death (arm A) due to acute leukemia. Mean treatment cost was lower for arm B compared with arm A (P = 0.02).Conclusions:The two-drug CbD regimen yielded pCR, RCB 0+I, and survival rates similar to the four-drug regimen of CbP → AC, but with a more favorable toxicity profile and lower treatment-associated cost.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)
Purpose:Addition of carboplatin (Cb) to anthracycline chemotherapy improves pathologic complete response (pCR), and carboplatin plus taxane regimens also yield encouraging pCR rates in triple-negative breast cancer (TNBC). Aim of the NeoSTOP multisite randomized phase II trial was to assess efficacy of anthracycline-free and anthracycline-containing neoadjuvant carboplatin regimens.Patients and Methods:Patients aged ≥18 years with stage I–III TNBC were randomized (1:1) to receive either paclitaxel (P) weekly × 12 plus carboplatin AUC6 every 21 days × 4 followed by doxorubicin/cyclophosphamide (AC) every 14 days × 4 (CbP → AC, arm A), or carboplatin AUC6 + docetaxel (D) every 21 days × 6 (CbD, arm B). Stromal tumor-infiltrating lymphocytes (sTIL) were assessed. Primary endpoint was pCR in breast and axilla. Other endpoints included residual cancer burden (RCB), toxicity, cost, and event-free (EFS) and overall survival (OS).Results:One hundred patients were randomized; arm A (n = 48) or arm B (n = 52). pCR was 54% [95% confidence interval (CI), 40%–69%] in arm A and 54% (95% CI, 40%–68%) in arm B. RCB 0+I rate was 67% in both arms. Median sTIL density was numerically higher in those with pCR compared with those with residual disease (20% vs. 5%; P = 0.25). At median follow-up of 38 months, EFS and OS were similar in the two arms. Grade 3/4 adverse events were more common in arm A compared with arm B, with the most notable differences in neutropenia (60% vs. 8%; P < 0.001) and febrile neutropenia (19% vs. 0%; P < 0.001). There was one treatment-related death (arm A) due to acute leukemia. Mean treatment cost was lower for arm B compared with arm A (P = 0.02).Conclusions:The two-drug CbD regimen yielded pCR, RCB 0+I, and survival rates similar to the four-drug regimen of CbP → AC, but with a more favorable toxicity profile and lower treatment-associated cost.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)
Purpose:Addition of carboplatin (Cb) to anthracycline chemotherapy improves pathologic complete response (pCR), and carboplatin plus taxane regimens also yield encouraging pCR rates in triple-negative breast cancer (TNBC). Aim of the NeoSTOP multisite randomized phase II trial was to assess efficacy of anthracycline-free and anthracycline-containing neoadjuvant carboplatin regimens.Patients and Methods:Patients aged ≥18 years with stage I–III TNBC were randomized (1:1) to receive either paclitaxel (P) weekly × 12 plus carboplatin AUC6 every 21 days × 4 followed by doxorubicin/cyclophosphamide (AC) every 14 days × 4 (CbP → AC, arm A), or carboplatin AUC6 + docetaxel (D) every 21 days × 6 (CbD, arm B). Stromal tumor-infiltrating lymphocytes (sTIL) were assessed. Primary endpoint was pCR in breast and axilla. Other endpoints included residual cancer burden (RCB), toxicity, cost, and event-free (EFS) and overall survival (OS).Results:One hundred patients were randomized; arm A (n = 48) or arm B (n = 52). pCR was 54% [95% confidence interval (CI), 40%–69%] in arm A and 54% (95% CI, 40%–68%) in arm B. RCB 0+I rate was 67% in both arms. Median sTIL density was numerically higher in those with pCR compared with those with residual disease (20% vs. 5%; P = 0.25). At median follow-up of 38 months, EFS and OS were similar in the two arms. Grade 3/4 adverse events were more common in arm A compared with arm B, with the most notable differences in neutropenia (60% vs. 8%; P < 0.001) and febrile neutropenia (19% vs. 0%; P < 0.001). There was one treatment-related death (arm A) due to acute leukemia. Mean treatment cost was lower for arm B compared with arm A (P = 0.02).Conclusions:The two-drug CbD regimen yielded pCR, RCB 0+I, and survival rates similar to the four-drug regimen of CbP → AC, but with a more favorable toxicity profile and lower treatment-associated cost.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)
Purpose:Addition of carboplatin (Cb) to anthracycline chemotherapy improves pathologic complete response (pCR), and carboplatin plus taxane regimens also yield encouraging pCR rates in triple-negative breast cancer (TNBC). Aim of the NeoSTOP multisite randomized phase II trial was to assess efficacy of anthracycline-free and anthracycline-containing neoadjuvant carboplatin regimens.Patients and Methods:Patients aged ≥18 years with stage I–III TNBC were randomized (1:1) to receive either paclitaxel (P) weekly × 12 plus carboplatin AUC6 every 21 days × 4 followed by doxorubicin/cyclophosphamide (AC) every 14 days × 4 (CbP → AC, arm A), or carboplatin AUC6 + docetaxel (D) every 21 days × 6 (CbD, arm B). Stromal tumor-infiltrating lymphocytes (sTIL) were assessed. Primary endpoint was pCR in breast and axilla. Other endpoints included residual cancer burden (RCB), toxicity, cost, and event-free (EFS) and overall survival (OS).Results:One hundred patients were randomized; arm A (n = 48) or arm B (n = 52). pCR was 54% [95% confidence interval (CI), 40%–69%] in arm A and 54% (95% CI, 40%–68%) in arm B. RCB 0+I rate was 67% in both arms. Median sTIL density was numerically higher in those with pCR compared with those with residual disease (20% vs. 5%; P = 0.25). At median follow-up of 38 months, EFS and OS were similar in the two arms. Grade 3/4 adverse events were more common in arm A compared with arm B, with the most notable differences in neutropenia (60% vs. 8%; P < 0.001) and febrile neutropenia (19% vs. 0%; P < 0.001). There was one treatment-related death (arm A) due to acute leukemia. Mean treatment cost was lower for arm B compared with arm A (P = 0.02).Conclusions:The two-drug CbD regimen yielded pCR, RCB 0+I, and survival rates similar to the four-drug regimen of CbP → AC, but with a more favorable toxicity profile and lower treatment-associated cost.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)
Treatment completion by study arm
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)
Treatment completion by study arm
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)
Treatment completion by study arm
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)
Treatment completion by study arm